<DOC>
	<DOC>NCT00973323</DOC>
	<brief_summary>This study was a randomized, parallel group, open label trial using warfarin as comparator. Pharmacokinetics (PK) and pharmacodynamics (PD) were investigated only in BAY59-7939 groups (originally described in Japanese).</brief_summary>
	<brief_title>BAY59-7939 Japanese in Atrial Fibrillation (2nd)</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Japanese subjects with nonvalvular AF who met all of the following criteria: Persistent or paroxysmal nonvalvular AF with &gt;/=2 episodes before enrollment, at least 1 of which had been verified by ECG recording within 4 weeks before randomization Male subjects aged 20 years or older and postmenopausal female subjects Subjects with at least one risk factor for thromboembolism or aged 60 years or older (Risk factor for thromboembolism: hypertension, diabetes mellitus, coronary artery disease, congestive heart failure). History or presence of stroke or transient ischemic attack. History of intracerebral hemorrhage. History or presence of bleeding at randomization; intraocular or gastrointestinal bleeding within the last 6 months prior to randomization.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>BAY59-7939</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Non-valvular atrial fibrillation</keyword>
	<keyword>Japanese Patients</keyword>
	<keyword>Phase II</keyword>
</DOC>